An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis

A. Di Leo, E. Bajetta, L. Biganzoli, S. Bohm, L. Mariani, S. Mènard, S. Pilotti, M. Fabbiani, V. Gebbia, S. Oriana, F. Ottone, G. Riboldi, C. Sava, G. Spatti, F. Zunino, F. Di Re

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of the present study was to determine the activity of a combined regimen of mitoxantrone (DHAD) and ifosfamide (IFO) and identify clinical and biological factors with prognostic importance for the second-line treatment of ovarian cancer. The following factors were investigated for their prognostic importance: age, disease sites, platinum responsiveness, histological grade, the presence of clinically/radiologically detectable versus not detectable disease, residual disease volume after first surgery, p53 protein, c-erbB-2 oncoprotein and laminin receptor. 72 patients entered the trial. DHAD and IFO therapy led to a 15% response rate among the 47 cases with clinically/radiologically detectable disease (1 complete and 6 partial responses), with a median response duration of 4 months. The response rate was significantly different according to platinum responsiveness (4% objective responses in platinum-resistant versus 27% in platinum-sensitive disease). The time to treatment failure (TTF) and overall survival (OS) were affected by the presence of clinically detectable disease at study entry (median TTF 4 months in the presence of clinically/radiologically detectable disease versus 9 months if the disease was not similarly detectable, P = 0.02; median OS 10 months versus 21 months, P = 0.01). Initially overexpressed in only a few tumours, the c-erbB-2 oncoprotein became overexpressed in 36% of platinum-resistant tumours; this modulation did not occur in platinum-sensitive tumours. Furthermore, laminin receptor was expressed in 77% of platinum-sensitive versus 39% of platinum-resistant patients. There were no differences in p53 protein expression according to drug responsiveness.

Original languageEnglish
Pages (from-to)2248-2254
Number of pages7
JournalEuropean Journal of Cancer
Volume31
Issue number13-14
DOIs
Publication statusPublished - 1995

Keywords

  • ovarian cancer
  • prognostic factors
  • second-line treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis'. Together they form a unique fingerprint.

Cite this